⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30938561 | 0.98 | GABBR2 (0.95) | — | |
| SCHEMBL27819678 | 0.98 | GABBR2 (0.95) | — | |
| SCHEMBL11429786 | 0.84 | GABBR2 (0.71) | — | |
| Sgs-742 SCHEMBL195133 | 0.83 | GABBR2 (1.00) | — | |
| SCHEMBL2353617 | 0.83 | GABBR2 (0.83) | — | |
| SCHEMBL11593686 | 0.81 | GABBR2 (0.68) | — | |
| SCHEMBL6351264 | 0.81 | GABBR2 (0.87) | — | |
| Sgs-742 SCHEMBL6024389 | 0.81 | GABBR2 (0.95) | — | |
| Butylamine SCHEMBL29153171 | 0.80 | GABBR2 (0.67) | — | |
| SCHEMBL6358928 | 0.79 | GABBR2 (0.83) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1372620-A2 | METHODS FOR RESTORING COGNITIVE FUNCTION FOLLOWING SYSTEMIC STRESS | Saegis Pharmaceuticals (US) | 2004-01-02 | — | — | EP | claimed |
| US-20020187977-A1 | Methods for restoring cognitive function following systemic stress | SAEGIS PHARMACEUTICALS, INC. | 2002-12-12 | — | — | US | claimed |
| WO-2002074293-A2 | METHODS FOR RESTORING COGNITIVE FUNCTION FOLLOWING SYSTEMIC STRESS | SAEGIS PHARMACEUTICALS INC (US) | 2002-09-26 | — | — | WO | claimed |
| US-9035088-B2 | Method for producing mono-aminofunctionalized dialkylphosphinic acids and esters and salts thereof by means of acrylnitriles and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2015-05-19 | — | — | US | disclosed |
| CN-102186866-B | Method for producing mono amino-functionalised dialkylphosphinite acids esters and salts and use thereof | CLARIANT INT LTD | 2015-04-29 | — | — | CN | disclosed |
| EP-2373666-B1 | METHOD FOR PRODUCING MONO-AMINOFUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ACRYLNITRILES AND USE THEREOF | CLARIANT FINANCE BVI LTD (VG) | 2014-09-24 | — | — | EP | disclosed |
| US-8604232-B2 | Method for producing monoamino-functionalised dialkylphosphinite acids esters and salts and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2013-12-10 | — | — | US | disclosed |
| EP-2352741-B1 | METHOD FOR PRODUCING MONO AMINO-FUNCTIONALISED DIALKYLPHOSPHINITE ACIDS ESTERS AND SALTS AND USE THEREOF | CLARIANT INT LTD (CH) | 2013-08-28 | — | — | EP | disclosed |
| EP-2373666-A1 | METHOD FOR PRODUCING MONO-AMINOFUNCTIONALIZED DIALKYLPHOSPHINIC ACIDS AND ESTERS AND SALTS THEREOF BY MEANS OF ACRYLNITRILES AND USE THEREOF | Clariant Finance (BVI) Limited (VG) | 2011-10-12 | — | — | EP | disclosed |
| US-20110213061-A1 | Method for Producing Mono-Aminofunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-01 | — | — | US | disclosed |
| US-20110213079-A1 | Method for Producing Monoamino-Functionalised Dialkylphosphinite Acids Esters and Salts and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-09-01 | — | — | US | disclosed |
| EP-1372620-A2 | METHODS FOR RESTORING COGNITIVE FUNCTION FOLLOWING SYSTEMIC STRESS | Saegis Pharmaceuticals (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20020187977-A1 | Methods for restoring cognitive function following systemic stress | SAEGIS PHARMACEUTICALS, INC. | 2002-12-12 | — | — | US | disclosed |
| WO-2002074293-A2 | METHODS FOR RESTORING COGNITIVE FUNCTION FOLLOWING SYSTEMIC STRESS | SAEGIS PHARMACEUTICALS INC (US) | 2002-09-26 | — | — | WO | disclosed |
| EP-0319482-B1 | Novel substituted propane phosphinic acid compounds | CIBA GEIGY AG (CH) | 1994-05-18 | — | — | EP | disclosed |
| US-5300679-A | Antagonists to 4-aminobutyric acid | CIBA-GEIGY CORPORATION (US) | 1994-04-05 | — | — | US | disclosed |
| US-5190933-A | Treatment of cognitive and memory disorders | CIBA-GEIGY CORPORATION (US) | 1993-03-02 | — | — | US | disclosed |
| US-5064819-A | Antidepressants, anxiolytic agents, GABA antagonists | CIBA-GEIGY CORPORATION (US) | 1991-11-12 | — | — | US | disclosed |
| US-5051524-A | Treatment of a phosphinic acid with an anhydrous protic medium | CIBA-GEIGY CORPORATION (US) | 1991-09-24 | — | — | US | disclosed |
| US-5013863-A | Learning enhancement | CIBA-GEIGY CORPORATION (US) | 1991-05-07 | — | — | US | disclosed |